Wednesday, June 10, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· Chronic Spontaneous Urticaria Β· Asthma

Novartis India

Novartis Pharmaceuticals

Novartis India clinical programs β€” 145 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Founded
1996
Employees
2,240
Programs
341
Drugs
317
Patents
0
Official website β†— All projects Drug pipeline News & analysis
Intelligence Β· Clinical Programs

Novartis India projects

145 ClinicalTrials.gov programs sponsored by Novartis India.

Novartis India has 145 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

145 programs

Clinical programs

Page 2 of 4

  1. CLOU064P12301

    Novartis Pharmaceuticals

    Secondary progressive multiple sclerosis

    phase 3 small molecule active

    1 trial

  2. CNIO752A12301

    Novartis Pharmaceuticals

    Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

    phase 3 small molecule active

    1 trial

  3. COAV101A12308

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  4. COMB157G23101

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  5. COMB157G2399

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  6. COMB157G3301

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  7. CPI-0610, CPI-0610

    Novartis Pharmaceuticals

    Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

    phase 3 small molecule active

    1 trial

  8. CTQJ230A12301

    Novartis Pharmaceuticals

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  9. CTQJ230A12302

    Novartis Pharmaceuticals

    Apheresis

    phase 3 small molecule active

    1 trial

  10. CTQJ230A12304

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  11. CVAY736A2301

    Novartis Pharmaceuticals

    SjΓΆgren’s Syndrome

    phase 3 small molecule active

    1 trial

  12. CVAY736A2302

    Novartis Pharmaceuticals

    SjΓΆgren’s Syndrome

    phase 3 small molecule active

    1 trial

  13. CVAY736B2201

    Novartis Pharmaceuticals

    Autoimmune hepatitis

    phase 3 small molecule active

    1 trial

  14. CVAY736F12301

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  15. CVAY736F12302

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  16. CVAY736K12301

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  17. CVAY736K12301E1

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  18. CVAY736O12301

    Novartis Pharmaceuticals

    warm autoimmune haemolytic anaemia (wAIHA)

    phase 3 small molecule active

    1 trial

  19. CVAY736Q12301

    Novartis Pharmaceuticals

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  20. Capmatinib

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule terminated

    1 trial

  21. Dabrafenib

    Novartis Pharmaceuticals

    Malignant Melanoma

    phase 3 small molecule completed

    1 trial

  22. Deferasirox

    Novartis Pharmaceuticals

    Transfusion-dependent Iron Overload

    phase 3 small molecule completed

    1 trial

  23. EVEROLIMUS

    Novartis Pharmaceuticals

    Refractory seizures associated with tuberous sclerosis complex

    phase 3 small molecule active

    1 trial

  24. Everolimus

    Novartis Pharmaceuticals

    Advanced NET of GI Origin

    phase 3 small molecule completed

    1 trial

  25. Fingolimod

    Novartis Pharmaceuticals

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  26. Fulvestrant

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  27. Fulvestrant

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  28. Glycopyrronium bromide

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  29. INCLISIRAN, -

    Novartis Pharmaceuticals

    Familial hypercholsterolemia

    phase 3 small molecule active

    1 trial

  30. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  31. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical hemolytic uremic syndrome

    phase 3 small molecule active

    1 trial

  32. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  33. IPTACOPAN HYDROCHLORIDE

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  34. IPTACOPAN, LNP023

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  35. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia (ITP)

    phase 3 mab active

    1 trial

  36. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia

    phase 3 mab active

    2 trials

  37. Inclisiran

    Novartis Pharmaceuticals

    Familial Hypercholesterolemia - Heterozygous

    phase 3 small molecule completed

    1 trial

  38. Indacaterol 150 ΞΌg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  39. Indacaterol 150 ΞΌg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    1 trial

  40. Investigators choice of SoC

    Novartis Pharmaceuticals

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  41. Iptacopan

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome

    phase 3 small molecule completed

    1 trial

  42. JDQ443

    Novartis Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  43. LCZ696 (sacubitril/valsartan)

    Novartis Pharmaceuticals

    Acute Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  44. LMF237 50/250 mg

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  45. LNP023

    Novartis Pharmaceuticals

    Primary IgA Nephropathy

    phase 3 small molecule active

    1 trial

  46. LOU064

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  47. LOU064 (blinded)

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  48. Lapatinib

    Novartis Pharmaceuticals

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Novartis India have?

145 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.